Johnson & Johnson’s $3.5 Billion Registered Debt Offering
December 05, 2013
Cravath represented the underwriters, led by BofA Merrill Lynch, Goldman, Sachs & Co., J.P. Morgan Securities, Citigroup, Deutsche Bank Securities and RBS, in connection with the US$3.5 billion registered debt offering of Johnson & Johnson, a company engaged in the manufacturing and sale of a broad range of products in the healthcare field. The transaction closed on December 5, 2013.
The Cravath team included partner Craig F. Arcella and associates Andy Ham and Thomas K. Wiesner II. Cameron S. Stanton also worked on this matter.
Related Practices & Industries
People
- Photo
-
-
J.D., 1998, Columbia Law SchoolHarlan Fiske Stone Scholar
-
B.A., 1995, Duke University
- New York
Education
Admitted In
Related News & Insights
Deals & Cases
March 12, 2025
Johnson & Johnson’s $5 Billion Registered Notes Offering and Concurrent €4 Billion Notes Offering
Cravath represented the underwriters in connection with the $5 billion registered notes offering of Johnson & Johnson, the world’s largest, most diversified healthcare products company. Cravath also represented the underwriters in connection with Johnson & Johnson’s concurrent €4 billion notes offering. Proceeds of both offerings will be used to finance the acquisition of Intra‑Cellular Therapies, Inc. by Johnson & Johnson. The transactions closed on February 20, 2025, and February 26, 2025, respectively.
